Included in the formulation
АТХ:J.05.A.X Other antiviral drugs
Pharmacodynamics:Antiviral agent - oligopeptide (histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine), by pharmacological action is close to alpha-interferon.
Inductor synthesis of endogenous interferons and activator of the natural killer system. Stimulates recognition and lysis of defective cells with cytotoxic lymphocytes. Effective in infections caused by viruses of influenza A and B, hepatitis C, herpes.
Has no general toxicity, allergenic, mutagenic, carcinogenic, embryotoxic and does not affect reproductive function.
An increase in the concentration of interferon is noted 2 hours after the administration of the drug; high concentration remains (in 2-2.5 times higher than the usual background) for 6-8 hours with a decrease to the initial values by the end of the day. Increased functional activity of natural killers is observed within 7 days after drug administration.
Pharmacokinetics:Rapidly penetrates into the blood plasma, where it interacts with immunocompetent cells.The determination of concentration is hampered by the close structural similarity of its metabolites to serum proteins.
Indications:Chronic recurrent genital herpes.
I.A50-A64.A60 Anogenital herpetic viral infection [herpes simplex]
Contraindications:Hypersensitivity; pregnancy; lactation period; age to 18 years.
Pregnancy and lactation:The drug is contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously. When the frequency of relapses in a year more than 6 and more than 5 days duration in first relapse 3 recommended administration dose of 10 mg at intervals of 1 day, the next relapse - 1-3 injections of 1 mg in a subsequent relapse - introducing at 1-3 0.1 mg.
When the frequency of relapses in a year less than 6 and less than the duration of 5 days, 3 recommended administration intervals of 1 day to 1 mg, next relapse - 1-3 injections of 0.1 mg.
Side effects:As side effects, weakness, dizziness, the formation of new elements of herpes rash are possible.
Overdose:No data. Treatment is symptomatic. There is no specific antidote.
Interaction:Can be administered in combination with acyclovir in a complex therapy of viraldiseases.
Special instructions:Before administration, the drug is dissolved in 1 ml of a 0.9% solution of sodium chloride.